Thought Leadership

 

Project History X: The Project That Outlived Its Parents

Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years...

Emerging Mechanisms in Obesity: NLRP3 inhibiton doesn’t move the scale

This past month, I have been immersed in obesity science, and one thing’s clear: not every...

Project History VII-IX: Why the Best Go/No-Go Research Starts by

Intro Teams often fail not because of a lack of data, but because of research that...

Its all to play for in the next generation of

It has been a quiet summer on the post front with holidays and then a few active projects...

What is Happening in Pain: The Next Wave of Sodium

Intro At the end of May, Eli Lilly announced a $1 billion deal with Site One Therapeutics...

Project History VI: Asset Landscaping for Pharma BD and why

When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you...

Most Recent

Project History X: The Project That Outlived Its Parents

Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years ago, I took over a project that was...

Emerging Mechanisms in Obesity: NLRP3 inhibiton doesn’t move the scale

This past month, I have been immersed in obesity science, and one thing’s clear: not every pathway moves the scales. After dissecting...

Project History VII-IX: Why the Best Go/No-Go Research Starts by Trying to Kill the Project

Intro Teams often fail not because of a lack of data, but because of research that confirms what they already believe. The...

Its all to play for in the next generation of obesity treatments – Viking Therapeutics

It has been a quiet summer on the post front with holidays and then a few active projects keeping us very but...

All Posts

Project History X: The Project That Outlived Its Parents

Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years ago, I took...

Emerging Mechanisms in Obesity: NLRP3 inhibiton doesn’t move the scale

This past month, I have been immersed in obesity science, and one thing’s clear: not every pathway...

Project History VII-IX: Why the Best Go/No-Go Research Starts by Trying to Kill the Project

Intro Teams often fail not because of a lack of data, but because of research that confirms what...

Its all to play for in the next generation of obesity treatments – Viking Therapeutics

It has been a quiet summer on the post front with holidays and then a few active projects keeping us...

What is Happening in Pain: The Next Wave of Sodium Channel Blockers

Intro At the end of May, Eli Lilly announced a $1 billion deal with Site One Therapeutics, a company...

Simon Says Listen to this Podcast

With the sun out and a few projects wrapping up, I have enjoyed longer dog walks and catching up on...

Simon joins panel discussion Behind the Headlines

Early this week, I joined Chris Spivey on PharmaTech.com’s Behind the Headlines to discuss several...